Predicting time to ovarian carcinoma recurrence using protein markers

Ji Yeon Yang, Kosuke Yoshihara, Kenichi Tanaka, Masayuki Hatae, Hideaki Masuzaki, Hiroaki Itamochi, Masashi Takano, Kimio Ushijima, Janos L. Tanyi, George Coukos, Yiling Lu, Gordon Mills, Roel G.W. Verhaak

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Patients with ovarian cancer are at high risk of tumor recurrence. Prediction of therapy outcome may provide therapeutic avenues to improve patient outcomes. Using reverse-phase protein arrays, we generated ovarian carcinoma protein expression profiles on 412 cases from TCGA and constructed a PRotein-driven index of OVARian cancer (PROVAR). PROVAR significantly discriminated an independent cohort of 226 high-grade serous ovarian carcinomas into groups of high risk and low risk of tumor recurrence as well as short-term and long-term survivors. Comparison with gene expression-based outcome classification models showed a significantly improved capacity of the protein-based PROVAR to predict tumor progression. Identification of protein markers linked to disease recurrence may yield insights into tumor biology. When combined with features known to be associated with outcome, such as BRCA mutation, PROVAR may provide clinically useful predictions of time to tumor recurrence.

Original languageEnglish (US)
Pages (from-to)3740-3750
Number of pages11
JournalJournal of Clinical Investigation
Volume123
Issue number9
DOIs
StatePublished - Sep 3 2013
Externally publishedYes

Fingerprint

Carcinoma
Recurrence
Neoplasms
Proteins
Protein Array Analysis
Ovarian Neoplasms
Survivors
Gene Expression
Mutation
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Yang, J. Y., Yoshihara, K., Tanaka, K., Hatae, M., Masuzaki, H., Itamochi, H., ... Verhaak, R. G. W. (2013). Predicting time to ovarian carcinoma recurrence using protein markers. Journal of Clinical Investigation, 123(9), 3740-3750. https://doi.org/10.1172/JCI68509

Predicting time to ovarian carcinoma recurrence using protein markers. / Yang, Ji Yeon; Yoshihara, Kosuke; Tanaka, Kenichi; Hatae, Masayuki; Masuzaki, Hideaki; Itamochi, Hiroaki; Takano, Masashi; Ushijima, Kimio; Tanyi, Janos L.; Coukos, George; Lu, Yiling; Mills, Gordon; Verhaak, Roel G.W.

In: Journal of Clinical Investigation, Vol. 123, No. 9, 03.09.2013, p. 3740-3750.

Research output: Contribution to journalArticle

Yang, JY, Yoshihara, K, Tanaka, K, Hatae, M, Masuzaki, H, Itamochi, H, Takano, M, Ushijima, K, Tanyi, JL, Coukos, G, Lu, Y, Mills, G & Verhaak, RGW 2013, 'Predicting time to ovarian carcinoma recurrence using protein markers', Journal of Clinical Investigation, vol. 123, no. 9, pp. 3740-3750. https://doi.org/10.1172/JCI68509
Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H et al. Predicting time to ovarian carcinoma recurrence using protein markers. Journal of Clinical Investigation. 2013 Sep 3;123(9):3740-3750. https://doi.org/10.1172/JCI68509
Yang, Ji Yeon ; Yoshihara, Kosuke ; Tanaka, Kenichi ; Hatae, Masayuki ; Masuzaki, Hideaki ; Itamochi, Hiroaki ; Takano, Masashi ; Ushijima, Kimio ; Tanyi, Janos L. ; Coukos, George ; Lu, Yiling ; Mills, Gordon ; Verhaak, Roel G.W. / Predicting time to ovarian carcinoma recurrence using protein markers. In: Journal of Clinical Investigation. 2013 ; Vol. 123, No. 9. pp. 3740-3750.
@article{052a733da9a64bc885d7631c7d8e1be6,
title = "Predicting time to ovarian carcinoma recurrence using protein markers",
abstract = "Patients with ovarian cancer are at high risk of tumor recurrence. Prediction of therapy outcome may provide therapeutic avenues to improve patient outcomes. Using reverse-phase protein arrays, we generated ovarian carcinoma protein expression profiles on 412 cases from TCGA and constructed a PRotein-driven index of OVARian cancer (PROVAR). PROVAR significantly discriminated an independent cohort of 226 high-grade serous ovarian carcinomas into groups of high risk and low risk of tumor recurrence as well as short-term and long-term survivors. Comparison with gene expression-based outcome classification models showed a significantly improved capacity of the protein-based PROVAR to predict tumor progression. Identification of protein markers linked to disease recurrence may yield insights into tumor biology. When combined with features known to be associated with outcome, such as BRCA mutation, PROVAR may provide clinically useful predictions of time to tumor recurrence.",
author = "Yang, {Ji Yeon} and Kosuke Yoshihara and Kenichi Tanaka and Masayuki Hatae and Hideaki Masuzaki and Hiroaki Itamochi and Masashi Takano and Kimio Ushijima and Tanyi, {Janos L.} and George Coukos and Yiling Lu and Gordon Mills and Verhaak, {Roel G.W.}",
year = "2013",
month = "9",
day = "3",
doi = "10.1172/JCI68509",
language = "English (US)",
volume = "123",
pages = "3740--3750",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "9",

}

TY - JOUR

T1 - Predicting time to ovarian carcinoma recurrence using protein markers

AU - Yang, Ji Yeon

AU - Yoshihara, Kosuke

AU - Tanaka, Kenichi

AU - Hatae, Masayuki

AU - Masuzaki, Hideaki

AU - Itamochi, Hiroaki

AU - Takano, Masashi

AU - Ushijima, Kimio

AU - Tanyi, Janos L.

AU - Coukos, George

AU - Lu, Yiling

AU - Mills, Gordon

AU - Verhaak, Roel G.W.

PY - 2013/9/3

Y1 - 2013/9/3

N2 - Patients with ovarian cancer are at high risk of tumor recurrence. Prediction of therapy outcome may provide therapeutic avenues to improve patient outcomes. Using reverse-phase protein arrays, we generated ovarian carcinoma protein expression profiles on 412 cases from TCGA and constructed a PRotein-driven index of OVARian cancer (PROVAR). PROVAR significantly discriminated an independent cohort of 226 high-grade serous ovarian carcinomas into groups of high risk and low risk of tumor recurrence as well as short-term and long-term survivors. Comparison with gene expression-based outcome classification models showed a significantly improved capacity of the protein-based PROVAR to predict tumor progression. Identification of protein markers linked to disease recurrence may yield insights into tumor biology. When combined with features known to be associated with outcome, such as BRCA mutation, PROVAR may provide clinically useful predictions of time to tumor recurrence.

AB - Patients with ovarian cancer are at high risk of tumor recurrence. Prediction of therapy outcome may provide therapeutic avenues to improve patient outcomes. Using reverse-phase protein arrays, we generated ovarian carcinoma protein expression profiles on 412 cases from TCGA and constructed a PRotein-driven index of OVARian cancer (PROVAR). PROVAR significantly discriminated an independent cohort of 226 high-grade serous ovarian carcinomas into groups of high risk and low risk of tumor recurrence as well as short-term and long-term survivors. Comparison with gene expression-based outcome classification models showed a significantly improved capacity of the protein-based PROVAR to predict tumor progression. Identification of protein markers linked to disease recurrence may yield insights into tumor biology. When combined with features known to be associated with outcome, such as BRCA mutation, PROVAR may provide clinically useful predictions of time to tumor recurrence.

UR - http://www.scopus.com/inward/record.url?scp=84883528065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883528065&partnerID=8YFLogxK

U2 - 10.1172/JCI68509

DO - 10.1172/JCI68509

M3 - Article

C2 - 23945238

AN - SCOPUS:84883528065

VL - 123

SP - 3740

EP - 3750

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 9

ER -